Elucidating the Reprograming of Colorectal Cancer Metabolism Using Genome-Scale Metabolic Modeling

Overview

Journal Front Oncol

Specialty Oncology

Date 2019 Aug 17

PMID 31417867

Citations 16

Authors

Cheng Zhang

Mohammed Aldrees

Muhammad Arif

Xiangyu Li

Adil Mardinoglu

Mohammad Azhar Aziz

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer is the third most incidental cancer worldwide, and the response rate of current treatment for colorectal cancer is very low. Genome-scale metabolic models (GEMs) are systems biology platforms, and they had been used to assist researchers in understanding the metabolic alterations in different types of cancer. Here, we reconstructed a generic colorectal cancer GEM by merging 374 personalized GEMs from the Human Pathology Atlas and used it as a platform for systematic investigation of the difference between tumor and normal samples. The reconstructed model revealed the metabolic reprogramming in glutathione as well as the arginine and proline metabolism in response to tumor occurrence. In addition, six genes including ODC1, SMS, SRM, RRM2, SMOX, and SAT1 associated with arginine and proline metabolism were found to be key players in this metabolic alteration. We also investigated these genes in independent colorectal cancer patients and cell lines and found that many of these genes showed elevated level in colorectal cancer and exhibited adverse effect in patients. Therefore, these genes could be promising therapeutic targets for treatment of a specific colon cancer patient group.

Citing Articles

The functional correlation between mir-16-5p and BIRC5 gene in colorectal cancer: integrated analysis of transcriptomics and in vitro validation.

Aslan E, Yavas C, Akcali N, Eslamkhah S, Meral G, Batur L Mol Biol Rep. 2025; 52(1):252.

PMID: 39976834 DOI: 10.1007/s11033-025-10355-z.

From Data to Cure: A Comprehensive Exploration of Multi-omics Data Analysis for Targeted Therapies.

Mukherjee A, Abraham S, Singh A, Balaji S, Mukunthan K Mol Biotechnol. 2024; .

PMID: 38565775 DOI: 10.1007/s12033-024-01133-6.

Targeting metabolic fluxes reverts metastatic transitions in ovarian cancer.

Arora G, Banerjee M, Langthasa J, Bhat R, Chatterjee S iScience. 2023; 26(11):108081.

PMID: 37876796 PMC: 10590820. DOI: 10.1016/j.isci.2023.108081.

Genome-scale models as a vehicle for knowledge transfer from microbial to mammalian cell systems.

Strain B, Morrissey J, Antonakoudis A, Kontoravdi C Comput Struct Biotechnol J. 2023; 21:1543-1549.

PMID: 36879884 PMC: 9984296. DOI: 10.1016/j.csbj.2023.02.011.

Whole-cell energy modeling reveals quantitative changes of predicted energy flows in RAS mutant cancer cell lines.

Sevrin T, Strasser L, Ternet C, Junk P, Caffarini M, Prins S iScience. 2023; 26(2):105931.

PMID: 36711246 PMC: 9874014. DOI: 10.1016/j.isci.2023.105931.

References

Ha H, Sirisoma N, Kuppusamy P, Zweier J, Woster P, Casero Jr R . The natural polyamine spermine functions directly as a free radical scavenger. Proc Natl Acad Sci U S A. 1998; 95(19):11140-5. PMC: 21609. DOI: 10.1073/pnas.95.19.11140. View

Mardinoglu A, Nielsen J . New paradigms for metabolic modeling of human cells. Curr Opin Biotechnol. 2015; 34:91-7. DOI: 10.1016/j.copbio.2014.12.013. View

Pardini B, Kumar R, Naccarati A, Novotny J, Prasad R, Forsti A . 5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes. Br J Clin Pharmacol. 2011; 72(1):162-3. PMC: 3141199. DOI: 10.1111/j.1365-2125.2010.03892.x. View

Martinez M, OBrien T, Fultz K, Babbar N, Yerushalmi H, Qu N . Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci U S A. 2003; 100(13):7859-64. PMC: 164678. DOI: 10.1073/pnas.1332465100. View

Suzuki T, He Y, Kashiwagi K, Murakami Y, Hayashi S, Igarashi K . Antizyme protects against abnormal accumulation and toxicity of polyamines in ornithine decarboxylase-overproducing cells. Proc Natl Acad Sci U S A. 1994; 91(19):8930-4. PMC: 44720. DOI: 10.1073/pnas.91.19.8930. View

Borgan E, Sitter B, Lingjaerde O, Johnsen H, Lundgren S, Bathen T . Merging transcriptomics and metabolomics--advances in breast cancer profiling. BMC Cancer. 2010; 10:628. PMC: 2996395. DOI: 10.1186/1471-2407-10-628. View

Beloribi-Djefaflia S, Vasseur S, Guillaumond F . Lipid metabolic reprogramming in cancer cells. Oncogenesis. 2016; 5:e189. PMC: 4728678. DOI: 10.1038/oncsis.2015.49. View

Liu M, Wang X, Wang L, Ma X, Gong Z, Zhang S . Targeting the IDO1 pathway in cancer: from bench to bedside. J Hematol Oncol. 2018; 11(1):100. PMC: 6090955. DOI: 10.1186/s13045-018-0644-y. View

Hecht J, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D . A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2008; 27(5):672-80. DOI: 10.1200/JCO.2008.19.8135. View

10.

Haller D, Catalano P, Macdonald J, ORourke M, Frontiera M, Jackson D . Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005; 23(34):8671-8. DOI: 10.1200/JCO.2004.00.5686. View

11.

Heidel J, Liu J, Yen Y, Zhou B, Heale B, Rossi J . Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin Cancer Res. 2007; 13(7):2207-15. DOI: 10.1158/1078-0432.CCR-06-2218. View

12.

Brenner H, Kloor M, Pox C . Colorectal cancer. Lancet. 2013; 383(9927):1490-1502. DOI: 10.1016/S0140-6736(13)61649-9. View

13.

Lewis N, Abdel-Haleem A . The evolution of genome-scale models of cancer metabolism. Front Physiol. 2013; 4:237. PMC: 3759783. DOI: 10.3389/fphys.2013.00237. View

14.

Mardinoglu A, Gatto F, Nielsen J . Genome-scale modeling of human metabolism - a systems biology approach. Biotechnol J. 2013; 8(9):985-96. DOI: 10.1002/biot.201200275. View

15.

Bloem L, De Abreu Lourenco R, Chin M, Ly B, Haas M . Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer. Oncol Ther. 2017; 4(1):103-116. PMC: 5315063. DOI: 10.1007/s40487-016-0020-4. View

16.

Aziz M, Yousef Z, Saleh A, Mohammad S, Al Knawy B . Towards personalized medicine of colorectal cancer. Crit Rev Oncol Hematol. 2017; 118:70-78. DOI: 10.1016/j.critrevonc.2017.08.007. View

17.

Ghaffari P, Mardinoglu A, Nielsen J . Cancer Metabolism: A Modeling Perspective. Front Physiol. 2016; 6:382. PMC: 4679931. DOI: 10.3389/fphys.2015.00382. View

18.

Saltz L, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R . Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26(12):2013-9. DOI: 10.1200/JCO.2007.14.9930. View

19.

Varemo L, Nielsen J, Nookaew I . Enriching the gene set analysis of genome-wide data by incorporating directionality of gene expression and combining statistical hypotheses and methods. Nucleic Acids Res. 2013; 41(8):4378-91. PMC: 3632109. DOI: 10.1093/nar/gkt111. View

20.

Mardinoglu A, Boren J, Smith U, Uhlen M, Nielsen J . Systems biology in hepatology: approaches and applications. Nat Rev Gastroenterol Hepatol. 2018; 15(6):365-377. DOI: 10.1038/s41575-018-0007-8. View